Key result
Dabigatran was associated with a lower risk of ischemic stroke or systemic embolism compared with warfarin (aHR 0.86; 95% CI 0.79-0.93) but a higher risk of gastrointestinal bleeding.
Why the study?
Does dabigatran reduce the risk of ischemic stroke or systemic embolism compared to warfarin in real-world US patients with non-valvular atrial fibrillation?
Population
64,935 patients with non-valvular atrial fibrillation initiating anticoagulation from October 2010 to…
Comparison
Dabigatran vs Warfarin
Design
Cohort
Authors
Loading...
May guide anticoagulant selection in real-world US NVAF; extends RCTs but should not yet change practice.
Cohort (n=64,935)
Yes
Does dabigatran reduce the risk of ischemic stroke or systemic embolism compared to warfarin in real-world US patients with non-valvular atrial fibrillation?
Effect estimate: aHR 0.86 (95% CI 0.79-0.93)
In a real-world US cohort of patients with non-valvular atrial fibrillation, dabigatran was associated with lower risks of ischemic stroke, systemic embolism, hemorrhagic stroke, and myocardial infarction compared to warfarin, but a higher risk of gastrointestinal bleeding.
Lauffenburger et al. (2015) conducted a cohort in Non-valvular atrial fibrillation (n=64,935). Dabigatran vs. Warfarin was evaluated on Ischemic stroke or systemic embolism (aHR 0.86, 95% CI 0.79-0.93). Dabigatran was associated with a lower risk of ischemic stroke or systemic embolism compared with warfarin (aHR 0.86; 95% CI 0.79-0.93) but a higher risk of gastrointestinal bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: